Genetic risk factors of venous thrombosis

Human Genetics

Volumn 109, Issue 4, 2001, Pages 369-384

  Franco, Rendrik F ^a,b   Reitsma, Pieter H ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; HORMONE; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTEIN S; PROTHROMBIN;

AGE; ANTIPHOSPHOLIPID SYNDROME; CANCER; CLINICAL FEATURE; ENVIRONMENTAL FACTOR; FRACTURE; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; IMMOBILIZATION; LIFESTYLE; LUNG EMBOLISM; MULTIFACTORIAL INHERITANCE; ORAL CONTRACEPTION; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUERPERIUM; REVIEW; RISK FACTOR; SURGICAL TECHNIQUE; VEIN THROMBOSIS;

ANTITHROMBINS; BLOOD COAGULATION FACTORS; FACTOR V; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; HYPERHOMOCYSTEINEMIA; MUTATION; PROTEIN C; PROTEIN S; PROTHROMBIN; RISK FACTORS; VENOUS THROMBOSIS;

EID: 0035159120     PISSN: 03406717     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004390100593     Document Type: Review

References (213)

1. Antithrombin and related inhibitors of coagulation
2. A review of mutations causing deficiencies of antithrombin, protein C and protein S
3. The FXIII Val 34 Leu mutation and the risk of venous thrombosis
4. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect
5. The factor XIII polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure
6. Polymorphisms in the 5′ regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: The ECTIM and PATHROS studies. Étude Cas-Temoins de l'Infarctus du Myocarde. Paris Thrombosis Case-Control Study
7. Ethnic heterogeneity of the factor XIII Val34Leu polymorphism
8. Risk of venous thrombosis in carriers of the prothrombin G20210 A variant and factor V Leiden and their interaction with oral contraceptives
9. Thrombophilia testing: What do we think the tests mean and what should we do with the results?
10. Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FV R506 K) mutation: Effect of warfarin and prediction by precipitating factors. East Anglian Thrombophilia Study
11. Val34Leu polymorphism of plasma factor XIII: Biochemistry and epidemiology in familial thrombophilia
12. Antithrombin: Molecular basis of deficiency
13. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel
14. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype
15. Mutation in blood coagulation factor V associated with resistance to activated protein C
16. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen
17. Characterization of the gene encoding human TAFI (thrombin-activatable fibrinolysis inhibitor; Plasma carboxypeptidase B)
18. Phospholipid antibodies and resistance to activated protein C in women with thrombophilia
19. Molecular basis for protein S hereditary deficiency: Genetic defects observed in 118 patients with type I and type IIa deficiencies. The French network on molecular abnormalities responsible for protein C and protein S deficiencies
20. Antithrombin and its inherited deficiency states
21. Hereditary antithrombin deficiency: Heterogeneity of the molecular basis and mortality in Dutch families
22. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency
23. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency
24. The G20210 A prothrombin polymorphism is not associated with increased thromboembolic risk in a large protein C deficient kindred
25. Recurrent phlebitis of obscure origin
26. Congenital protein C deficiency and venous thromboembolism: A study of three Dutch families
27. Effect of the MTHFRC677 T variant on risk of venous thromboembolism: Interaction with factor V Leiden and prothrombin (F2G20210 A) mutations
28. Tissue factor pathway inhibitor
29. Inhibition of factor VIIa/tissue factor by antithrombin III and tissue factor pathway inhibitor
30. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance. A multicenter collaborative family study
31. Hyperhomocysteinemia, atherosclerosis and thrombosis
32. A common mutation in the methylenetetrahydrofolate reductase gene (C677 T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506)
33. The G20210 A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: Prevalence and association with factor V G1691 A, methylenetetrahydrofolate reductase C677 T and plasma prothrombin levels
34. Association of a common polymorphism in the factor XIII gene with venous thrombosis
35. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese
36. Familial protein S deficiency is associated with recurrent thrombosis
37. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: Study of 78 women
38. Homozygous protein C deficiency with late onset and recurrent coumarin-induced skin necrosis
39. Antithrombin III: Associations with age, race, sex and cardiovascular disease risk factors. The atherosclerotic risk in communities (ARIC) study investigators
40. The FXIII Val34Leu polymorphism in venous and arterial thromboembolism
41. The prothrombin gene G20210 A variant: Prevalence in a UK anticoagulant clinic population
42. Homocysteine and thrombotic disease
43. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
44. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S
45. Inherited thrombophilia: Pathogenesis, clinical syndromes, and management
46. Prevalence of mild hyperhomocysteinemia and association with thrombophilic genotypes (factor V Leiden and prothrombin G20210 A) in Italian patients with venous thromboembolic disease
47. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210 A prothrombin mutation
48. Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism
49. Case-control study of the risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of prothrombotic conditions
50. Thrombosis in antithrombin III-deficient persons. Report of a large kindred and literature review
51. A study of protein S antigen levels in 3788 healthy volunteers: Influence of age, sex and hormone use, and estimate for prevalence of deficiency state
52. Inherited antithrombin III deficiency causing thrombophilia
53. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden
54. The risk of early recurrent venous thromboembolism after oral anticoagulation therapy in patients with the G20210 A transition in the prothrombin gene
55. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction
56. The endothelial protein C receptor
57. The C536 T transition in the tissue factor pathway inhibitor gene is not a common cause of venous thromboembolic disease in the UK population
58. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden)
59. High prevalence of hyperhomocysteinemia in patients with juvenile venous thrombosis
60. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease
61. Contribution of the cystathionine beta-synthase gene (844ins68) polymorphism to the risk of early-onset venous and arterial occlusive disease and fasting hyperhomocysteinemia
62. Factor V Arg306→Thr (factor V Cambridge) and factor V Arg306→Gly mutations in venous thrombotic disease
63. The prevalence of the G20210 A polymorphism in the 3′-untranslated region of the prothrombin gene in different human populations
64. Analysis of the 677 C→T mutation in the methylenetetrahydrofolate reductase gene in different ethnic groups
65. Heterogeneous ethnic distribution of the 844ins68 in the cystathionine β-synthase gene
66. The frequency of 844ins68 mutation in the cystathionine β-synthase gene is not increased in patients with venous thrombosis
67. Heterogeneous ethnic distribution of factor V Leiden mutation
68. The prevalence of factor V Arg306→Thr (factor V Cambridge) and factor V Arg306→Gly mutations in different human populations
69. The 20210 G→A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease
70. A second mutation in the methylenetetrahydrofolate reductase gene and the risk of venous thrombotic disease
71. Factor XIII Val34Leu is a genetic factor involved in the aetiology of venous thrombosis
72. Factor XIII Val34Leu and the risk of myocardial infarction
73. Factor XIII Val34Leu and the risk of venous thromboembolism in factor V Leiden carriers
74. Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: Relationship with plasma TAFI levels and risk of venous thrombosis
75. A candidate genetic risk factor for vascular disease: A common mutation in the methylenetetrahydrofolate reductase
76. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients
77. Incidence of activated protein C resistance due to Arg 506 Gln mutation in factor V in 116 unrelated propositus from families with protein S deficiency
78. Protein S deficiency: A database of mutations - Summary of the first update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
79. The TFPI 536C→T mutation is not associated with increased risk for venous or arterial thrombosis
80. Laboratory testing for heritable thrombophilia: Impact on clinical management of thrombotic disease
81. Activated protein C resistance caused by Arg506Gln mutation in factor Va
82. Deficiency of protein C in congenital thrombotic disease
83. Late-onset homozygous protein C deficiency
84. Population differences in the frequency of the factor V Leiden variant among people with clinically symptomatic protein C deficiency
85. The incidence of dysfunctional antithrombin variants: Four cases in 210 patients with thromboembolic disease
86. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis
87. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
88. Hyperhomocysteinemia and venous thrombosis: A meta-analysis
89. Pregnancy in women with congenital antithrombin III deficiency: Experience of treatment with heparin and antithrombin
90. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: Evidence that plasma TAFI antigen levels are strongly genetically controlled
91. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis
92. Congenital antithrombin III deficiency. Incidence and clinical features
93. A terminal peptide sequence of human haemoglobin?
94. High levels of factor IX increase the risk of venous thrombosis
95. Thrombomodulin gene mutations associated with myocardial infarction
96. The familial tendency in thromboembolic disease
97. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions
98. Elevated factor VIII levels and the risk of thrombosis
99. A prothrombin gene mutation is significantly associated with venous thrombosis
100. A comparison of three months of coagulation with extended anticoagulation for a first episode of idiopathic thromboembolism
101. A first mutation in the human tissue factor pathway inhibitor gene encoding [P151L]TFPI
102. The 536C→T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis
103. A common 844INS68 insertion variant in the cystathionine beta-synthase gene
104. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis
105. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families
106. Factor V Leiden: An additional risk factor for thrombosis in protein S deficient families?
107. Familial thrombophilia: A complex genetic disorder
108. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
109. Protein C deficiency in a controlled series of unselected outpatients: An infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study)
110. Role of clotting factor VIII in effect of von Willebrand factor on the occurrence of deep-vein thrombosis
111. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism
112. Identification and characterization of a thrombomodulin gene mutation coding for an elongated protein with reduced expression in a kindred with myocardial infarction
113. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease
114. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis
115. Mutations in promoter region of thrombomodulin and venous thromboembolic disease
116. Thrombomodulin promoter mutations, venous thrombosis, and varicose veins
117. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients
118. Factor V Leiden: The venous thrombotic risk in thrombophilic families
119. Venous thrombotic risk in family members of unselected individuals with factor V Leiden
120. Recurrent deep vein thrombosis and two coagulation factor gene mutations: Quo vadis?
121. Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients
122. The risk of recurrent venous thromboembolism in carriers and non carriers of the G2691 A allele in the coagulation factor V gene and the G20210 A allele in the prothrombin gene
123. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss - A possible evolutionary selection mechanism
124. The factor V R2 allele: Risk of venous thromboembolism, factor V levels and resistance to activated protein C
125. Hyperhomocysteinemia and thrombosis
126. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S
127. Coexistence of hereditary homocystinuria and factor V Leiden: Effects on thrombosis
128. Coexistence of factor V Leiden and factor II A20210 mutation and recurrent venous thromboembolism
129. Factor XIII Val34Leu polymorphism and risk of deep vein thrombosis
130. Human β-globin messenger RNA III. Nucleotide sequences derived from complementary DNA
131. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: A study of 150 families
132. High risk of cerebral-vein thrombosis in carriers of the prothrombin-gene mutation and in users of oral contraceptives
133. Interaction between the G20210 A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis
134. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both
135. High levels of coagulation factor XI as a risk factor for venous thrombosis
136. Congenital thrombophilia among patients with venous thromboembolism
137. A 23 bp insertion in the endothelial protein C receptor (EPCR) gene in patients with myocardial infarction and deep vein thrombosis
138. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis
139. G20210 A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism
140. Absence of thrombosis in subjects with heterozygous protein C deficiency
141. Molecular genetic analysis of severe protein C deficiency
142. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: Impact of the V264 M substitution on plasma levels of TFPI
143. A new T-287 C polymorphism in the 5′ regulatory region of the tissue factor pathway inhibitor gene. Association study of the T-287 C and C-399 T polymorphisms with coronary artery disease and plasma TFPI levels
144. Factor XIII V34L is not an additional genetic risk factor for venous thrombosis in factor V Leiden carriers
145. The natural history of homocystinuria due to cystathionine beta-synthase deficiency
146. Thrombomodulin with the Asp468Tyr mutation is expressed on the cell surface with normal cofactor activity for protein C activation
147. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis
148. A novel thrombomodulin gene mutation in a patient suffering from sagital sinus thrombosis
149. A common thrombomodulin amino acid dimorphism is associated with myocardial infarction
150. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: Role of increased synthesis and relationship to the acute phase reaction
151. Elevation of FVIII:C in venous thromboembolism is persistent and independent of the acute phase response
152. Thrombomodulin gene variations and thromboembolic disease
153. Complete nucleotide sequence of the antithrombin gene: Evidence for homologous recombination causing thrombophilia
154. Hereditary deficiency of antithrombin III, protein C and protein S: Prevalence in patients with a history of venous thrombosis and criteria for rational patient screening
155. Sickle cell anemia, a molecular disease
156. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
157. Molecular heterogeneity of inherited antithrombin III deficiency
158. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa
159. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity
160. World distribution of factor V Leiden
161. Protein C deficiency: From gene defects to disease
162. The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: Heterogeneity and founder effects
163. Protein C deficiency: A database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH
164. Prothrombin G20210 A, factor V Leiden, and factor XIII Val34Leu: Common mutations of blood coagulation factors and deep vein thrombosis in Austria
165. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
166. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism
167. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening
168. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risks of future venous thromboembolism
169. Probability of recurrence of thrombosis in patients with and without factor V Leiden
170. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden
171. Actions and interactions of antithrombin and heparin
172. Risk factors for venous thrombosis: Prevalence, risk, and interaction
173. Venous thrombosis: A multicausal disease
174. High levels of factor VIII and venous thrombosis
175. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
176. Geographic distribution of the 20210 G to A prothrombin variant
177. Factor XIII Val34Leu, factor XIII antigen and activity levels and risk of venous thrombosis
178. Genetic modulation of homocysteinemia
179. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism. Prevalence and risk assessment
180. In the presence of other inherited or acquired high-risk situations, the FV Cambridge mutation may be an additional thrombophilic risk factor, through its effect on APC sensitivity
181. Plasma protein S deficiency in familial thrombotic disease
182. Genetic screening of candidate genes for a prothrombotic interaction with type I protein C deficiency in a large kindred
183. Genetic susceptibility to venous thrombosis
184. Thrombophilia as a multigenic disorder
185. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn
186. Homozygous protein C deficiency with moderately severe clinical symptoms
187. Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan
188. Factor V Leiden increases the risk of thrombosis in patients with antiphospholipid antibodies
189. Hyperhomocisteinemia and deep vein thrombosis: A case control study
190. The risk of recurrent venous thromboembolism in patients with an Arg506 Gln mutation in the gene for factor V
191. Structural and functional implications of the intron/exon organization of the human endothelial cell protein C/activated protein C receptor (EPCR) gene: Comparison with the structure of CD1/major histocompatibility complex alpha1 and alpha2 domains
192. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: The GAIT study
193. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex
194. Resistance to activated protein C as a basis for venous thrombosis
195. Influence of demographic factors on antithrombin III activity in a healthy population
196. Thrombin activatable fibrinolysis inhibitor and the risk of deep vein thrombosis
197. Asymptomatic homozygous protein C deficiency
198. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII Val34Leu mutation
199. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
200. Medical progress: Oral contraceptives and the risk of venous thrombosis
201. A frequent thrombomodulin amino acid dimorphism is not associated with thrombophilia
202. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis
203. The HR2 haplotype of factor V: Effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis
204. Association of idiopathic thromboembolism with single point mutation at Arg506 of factor V
205. Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males
206. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity
207. Prevalence of antithrombin deficiency in healthy blood donors: A cross-sectional study
208. Factor V Cambridge: A new mutation (Arg306→Thr) associated with resistance to activated protein C
209. A single genetic origin for a common Caucasian risk factor for venous thrombosis
210. A single genetic origin for the common prothrombotic G20210 A polymorphism in the prothrombin gene
211. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis
212. Resistance to activated protein C as an additional genetic risk factor in inherited deficiency of protein S
213. Thrombophilia as a multigenic disease